Weekly shot tested to help breast cancer survivors lose weight
NCT ID NCT07257484
Summary
This study is exploring whether a weekly medication called tirzepatide is a practical and acceptable option for postmenopausal women who have survived hormone receptor-positive breast cancer and are living with obesity. Researchers want to see if participants are willing and able to take the medication for six months and if it helps with weight loss and improves overall health markers. The study involves 30 participants who will have monthly check-ins and undergo body scans and blood tests to track changes.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Weill Cornell Medicine
New York, New York, 10021, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.